EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
In this paper we provide an overview of EMT in human malignancies, and discuss contribution of EMT to the development of the resistance to Epidermal Growth Factor Receptor (EGFR) …
Epithelial-mesenchymal transition (EMT) beyond EGFR …
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a major advance in treating NSCLC with EGFR-activating mutations. However, acquired resistance, due partially …
An epithelial-mesenchymal transition gene signature predicts ... - PubMed
Jan 1, 2013 · Purpose: Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated …
Epithelial-mesenchymal transition (EMT) beyond EGFR …
Aug 15, 2018 · Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a major advance in treating NSCLC with EGFR-activating mutations. However, acquired resistance, …
Hypoxia Activated EGFR Signaling Induces Epithelial to …
EGF (Epidermal Growth Factor) is a known inducer of EMT and growth of A431 cells in the absence of oxygen led to increased expression of EGFR (EGF Receptor). Treatment of A431 …
Epithelial–mesenchymal transition (EMT) and its role in acquired ...
Jul 6, 2024 · Recent studies show that EMT contributes to resistance to cancer treatment, including epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in non …
A transcriptomic map of EGFR-induced epithelial-to-mesenchymal ...
Sep 8, 2022 · EGFR-mediated EMT conveyed through MAPK activation contributes to HNSCC progression upon induction of migration and invasion. A 5-gene risk score based on a novel …
An epithelial-mesenchymal transition (EMT) gene signature …
EMT has been associated with metastatic spread and EGFR inhibitor resistance. We developed and validated a robust 76-gene EMT signature using gene expression profiles from four …
CD70 is a therapeutic target upregulated in EMT-associated EGFR ...
Feb 13, 2023 · Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire resistance to …
How apoptosis and epithelial-to-mesenchymal transition are …
Therefore, re-establishing an apoptotic response in EMT-mediated EGFR mutant NSCLC resistant cells is a promising pharmaceutical strategy, in the landscape of a clinical trial …